The objective of this paper was to review a new category of gene therapy using oncolytic viruses for the treatment of pancreatic cancer. The eligibility and feasibility of oncolytic virus therapy as a novel therapeutic agent against pancreatic cancer are discussed as well as basic research for clinical trials, including a historical perspective and the current status of these novel agents. Even combination therapy, such as surgery with radiation and chemotherapy, has not significantly improved the survival rate of pancreatic cancer. Recently, a clinical trial (phase I and II) using an oncolytic adenovirus, ONYX-015, was completed in patients with pancreatic cancer. The phase II trial yielded beneficial results (tumor reduction or stabilization) in about 50% of the patients. A phase I study of the efficacy of oncolytic herpes viruses, G207, OncoVEX GM-CSF, and 1716 against a variety of tumors has been completed, and G207 is in phase II trials for use against brain tumors. In addition, a phase I trial using the herpesvirus showed good tolerance at all dosages. We discuss the basic scientific principles and current results of the above clinical trials with respect to these oncolytic viruses, and then compare the relative advantages and disadvantages of adenoviruses and herpesviruses as oncolytic agents. We also review the published literature on newly developed oncolytic viruses. The concept of oncolytic therapy has been studied for a century. Recent technological developments have made these oncolytic viruses more tumor-specific by exploiting the tumor cell environments. In addition, these viruses have been reported to increase the immunosusceptibility of the tumor cells, and have been designed to express other genes to increase the susceptibility of tumor cells to other therapeutic agents. Oncolytic virus therapy certainly appears to be a feasible treatment for pancreatic cancer.
T he prognosis of patients with pancreatic cancer is poor, with or without treatment. The National Cancer Institute (NCI) reported in its SEER Cancer Statistics Review that there are approximately 27,000 new cases of pancreatic cancer, resulting in around 26,000 deaths each year in the United States. The incidence of this cancer has been gradually increasing over the past 20 years, and it is now the fourth most common cause of cancer death. It accounts for only 2% of all newly diagnosed cancers in the United States each year, but 5% of all cancer deaths. Most pancreatic cancers are adenocarcinomas originating from pancreatic ductal cells having characteristic genetic alterations, such as K-ras (90%), CDKN2 (80%), p16 (75%), p53 (70%), or Smad4 (DPC4) (65%). The disease is often far advanced by the time symptoms occur, and a definitive diagnosis has been established. As indicated by a total 5-year survival rate of less than 5% from the time of diagnosis, treatment is rarely efficacious, even if the tumor is resectable, and the 5-year survival is less than 15% even in resectable cases. [1] [2] [3] [4] Islet cell carcinomas have a better prognosis, but account for less than 2% of all pancreatic cancers. Nevertheless, pancreatic cancer is extremely aggressive locally and frequently metastasizes to the liver and peritoneum. Combination therapy has been performed using radiation therapy or chemotherapy with or without surgery. Moreover, new methods for the evaluation of tumor invasion have been developed, such as the use of intraoperative ultrasound. [5] [6] [7] [8] Even so, the 3-year survival rate for patients with pancreatic cancer remains extremely low. New treatment strategies are clearly necessary, and oncolytic virus therapy offers hope in this regard. Recently, clinical trials of this therapy have been started against many types of cancer (Table 1) . We discuss the possibility and feasibility of oncolytic virus therapy, focusing on pancreatic cancer.
Historical background
Oncolytic virus therapy originated early in the last century upon the observation of occasional tumor regressions in cancer patients suffering from virus infections or those receiving vaccinations. The historical record of oncolytic virus therapy began in 1912 when DePace 9 described his work on uterine cervical carcinoma. He reported tumor regression after inoculation of an attenuated rabies vaccine. This report led to an animal experiment on tumor burden in 1920 by Levaditi and Nicolau, who first documented vaccinia viral oncolysis in the mouse. 10 Thus, even a century ago the viral oncolytic effect was known to possess a capacity for tumor regression. Subsequently, a human trial was performed in New York in 1940 by Pack 11 using an attenuated rabies virus against melanoma that yielded a remarkable partial remission. By midcentury, Southan in New York was treating large numbers of patients suffering various types of malignancies, using numerous viruses including myxovirus, paramyxovirus, and arbovirus. He documented the cause of tumor regression induced by these viruses. [12] [13] [14] [15] [16] Mechanisms of the oncolytic effect The oncolytic effect has several possible mechanisms that yield complex results. The first such mechanism is the result of viral replication within the cell and rupture out of the cell. This cycle is repeated with progeny virions infecting and replicating in neighboring cells. This is also a specific characteristic of a replication-competent virus vector. The second mechanism involves a few viruses producing cytotoxic protein during replication in cells, with the protein itself then causing damage to the cell. For example, late in the cell cycle, adenoviruses express the E3 11.6-kDa death protein that is cytotoxic to cells. 17, 18 The third mechanism involves virus infection of cancer cells that induces antitumoral immunity. Basically, the cancer cell antigen is a weak antigen for host immune sensitization. The virus infiltration causes inflammation and lymphocyte penetration into the tumor, and the virus protein leads to increased sensitivity to tumor necrosis factor-mediated killing (Fig 1) . The possibility exists that antitumor immunity remains as long-term protection against tumor recurrence. We demonstrated the immune acquisition after injection of the HSV-1 virus. Surviving mice acquired a resistance to rechallenge with tumor cells. 19 Host immune response maximizes antitumor immunity but also interferes with virus propagation. Wakimoto et al 20 studied the limitation of virus propagation caused by host immune response in the central nervous system. Ikeda et al 21 showed that the viral survival term was prolonged and that virus propagation was increased by the anti-immune drug, cyclophosphamide.
Representative oncolytic viruses for pancreatic cancer
Many types of oncolytic viruses have been studied as therapeutic agents. Oncolytic viruses for the treatment of pancreatic cancer studied in recent experimental and 27 E1B 55-kDa binds to the tumor suppressor protein p53 and, as a consequence, blocks p53-mediated transcriptional activations. 28, 29 ONYX-015 is thought to depend on alterations of the p53 tumor suppressor pathway for efficient replication in tumor cells. Motoi et al 30 in Japan demonstrated that the replication-competent adenovirus AxE1Adb, which is also an E1B 55-kDa gene-deleted adenovirus, attacked pancreatic cancer. AxE1Adb replicated itself inside pancreatic cancer cells and reduced the tumor size in mice in vivo. They also attempted to enhance the effect on the tumor; for this purpose, they found an enhanced effect of combination therapy from using a cytokine-producing replication-incompetent adenovirus in conjunction with AxE1Adb. ONYX-015 has undergone human trials in a phase (I and II) study for pancreatic cancer, further details of which are described in the section on clinical trials.
Adenovirus Ad.DF3-E1
The DF3 (Muc1) gene is overexpressed mainly in human breast and pancreatic cancers. Since Ad.DF3-E1 has a DF3 promoter-regulated E1A gene, the E1A gene is expressed only in a Muc1-producing cell. The replication of this virus is restricted to Muc1-producing cancer cell lines. Kurihara et al 31 demonstrated that Ad.DF3-E1 selectively replicated in breast cancer, exhibiting a breast cancer flank tumor-reducing effect. Although they did not deal with pancreatic cancer in their paper, it may be postulated that Ad.DF3-E1 may have a high potential for treating pancreatic cancer since it is a well-known Muc1-producing cancer.
Herpesvirus hrR3
The herpes simplex virus (HSV) is an enveloped, doublestranded DNA virus with a genome size of 152 kb. A tumor-specific replication-competent herpesvirus, hrR3, was derived from the wild-type HSV1-KOS by Goldstein and Weller. 32 hrR3 is an ICP6 gene-deleted virus that leaves thymidine kinase (TK) intact. ICP6 is related to the gene for producing ribonucleotide reductase, which is a key enzyme in the biosynthesis of DNA in all prokaryotic 
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and eukaryotic cells. Tumors are known to produce abundant ribonucleotide reductase. Therefore, hrR3 can replicate in the tumor selectively maintaining sensitivity to acyclovir and ganciclovir, both of which are related to the TK gene. hrR3 combined with ganciclovir treatment was effective in mice with peritoneally disseminated pancreatic cancer. This study showed a significant improvement in the survival rates of the treated group, with long-term survival (150 days) in 70% of the mice receiving hrR3 and ganciclovir, in contrast to all untreated mice that died within 90 days. No vector-related mortality was observed. X-gal tissue staining revealed blue-stained cells only in pancreatic cancer tumor nodules. 33 In addition, hrR3 has been reported to have the capacity for enhancing the expression of a gene delivered by an adeno-associated virus in malignant cells but not in normal cells. We showed the effect of combination therapy of these viruses for a pancreatic cancer cell line.
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NV1020
NV1020 (R7020) is derived from an HSV1, deleted TK gene, one of g34.5 (on IRL), and 15 kb over the region jointly shared between US (Unique Short) and UL (Unique Long) that includes ICP0, ICP4, and LATs. A 5.2-kb fragment of HSV-2 DNA and TK gene under the regulation of HSV-1 a4 promoter are inserted into this deleted 15 kb region (Fig 2) . Therefore, NV1020 still maintains sensitivity to acyclovir and ganciclovir. NV1020 was originally developed as a human immunization vaccine against HSV-1 and HSV-2 infections. Accordingly, it was tested as a potential oncolytic agent in preclinical models of pancreatic cancer, 35 hormoneresistant prostate cancer, 36 and chemotherapy/radiotherapy-resistant epidermoid cancer. 37 Researchers have demonstrated rapid tumor regression and safety in all of their work on NV1020. Advani et al 37 also showed that the tumor regression effect with NV1020 was accelerated when used with radiation as part of a combination therapy. A human clinical trial using this virus against colon cancer liver metastasis by catheter maneuver into the hepatic artery is presently underway at the Memorial Sloan-Kettering Cancer Center in New York City.
Reovirus
This virus is a nonenveloped double-stranded RNA virus, 85 nm wide, and comprises a genome enclosed by two concentric icosahedral protein capsids with minimal pathogenicity in human. In total, 90% of pancreatic cancers have the K-ras mutation, and replication of the reovirus is related to the high activity of oncogenic Ras, [38] [39] [40] that has been known to block apoptosis and anoikis. 41 Replication of this virus is inhibited in normal cells, but it can flourish in cells with highly activated Ras. When the reovirus infects the cells, a virus-blocking pathway is activated by the RNA-activated protein kinase (PKR) and the eIF2a pathway. However, in cells with an activated oncogenic Ras, PKR phosphorylation is impaired, and virus-blocking activity does not proceed. The mechanism by which Ras activation leads to PKR inactivation is unclear. Coffey et al 42 have demonstrated a significant tumor regression in 65-80% of mice by an injection of 10 7 plaque-forming units (PFU) of reovirus using mice fibroblastoma and human glioblastoma. Hirasawa et al 43 reported an improvement in the survival rate of mice bearing Lewis lung cancer metastasis. The reovirus shows considerable promise for the treatment of pancreatic cancer, suggesting that the mechanism of tumor selectivity should be further investigated.
Potentiality of other oncolytic viruses
Although other viruses have not been reported in basic experiments for pancreatic cancer, we describe some here since they have great potential as oncolytic viruses.
Adenovirus Ad337
Ad337 is an E1B 19-kDa deleted adenovirus. E1B 19-kDa was reported to be a powerful inhibitor of the apoptotic pathways, and although this gene may be important in Figure 2 NV1020 (R7020) is derived from an HSV1, deleted TK gene with 700 bp, one of g34.5 (on IRL), and 15 kb over the region jointly shared between US and UL that includes ICP0, ICP4, and LATs. 5.2-kb fragment of HSV-2 DNA and TK gene under the regulation of HSV-1 a4 promoter are inserted into this deleted 15 kb region.
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maintaining viral production in some cell types, this has not proved to be the case in many cancer cells. This gene restricts the replication in tumor cells and compromises the therapeutic efficacy of the adenoviral vector. Sauthoff reported that an adenoviral mutant with a deletion of the E1B 19-kDa gene is more effective at killing tumor cells than the parent virus. Furthermore, this virus is released more rapidly from the infected tumor cells, and its spread in a monolayer of cancer cells is increased compared with that of the parent virus. This effect is likely to be a consequence of the enhanced induction of apoptosis seen after the E1B 19-kDa deletion. 44 Harrison et al 45 demonstrated that the E1B 19-kDa gene deleted adenovirus expressed a stronger tumor-reducing effect than the parent virus in vivo.
Herpesvirus G207
Herpesvirus G207 is a tumor-specific replication-competent virus derived from wild-type HSV1-KOS, and has a double-mutation locus comprised of both ICP34.5 and also ICP6. ICP34.5 (g34.5) is associated with the protein synthesis of virus replication using the interaction with dephosphorylate eIF2a in infected cells (Fig 3) . [46] [47] [48] [49] [50] Replication of the g34.5-null virus is attenuated in normal cells. ICP6 is a key enzyme in virus replication, as described in the section on hrR3, and its deletion restricts the replication of this virus in tumor cells. This deficiency leaves the mutant virus only in dividing cells.
Intracerebral inoculation of G207 into owl monkeys at a dose of 10 9 PFU reportedly reduced tumor size and was well tolerated; however, 10 3 PFU of the wild type rapidly killed the monkeys. [51] [52] [53] G207 is an ICP6-and g34.5-deleted virus that leaves TK intact. Therefore, G207 maintains sensitivity to acyclovir and ganciclovir. 54 Generally, G207 has been studied in brain tumors. Since it has achieved encouraging results in phase I studies against such tumors, phase II studies are now underway.
OncoVEX GM-CSF
The mutated oncolytic virus is normally made from the parent virus that has been passaged in the laboratory over a long period. OncoVEX GM-CSF was made from fresh isolated herpesvirus that is expected to have a more sympathetic and strong cytotoxic effect on human cells than a long-term laboratory passaged virus. It is formed by a double deletion of the neurovirulence factor ICP34.5 gene and an insertion of the granulocyte/macrophagecolony stimulate factor (GM-CSF) into ICP47, which is then able to block the antigen produced in HSV-infected cells. The mutation of ICP47 is expected to stimulate host immune sensitivity in the infected cells, and the inserted GM-CSF gathers granulocytes and macrophages around those infected cells. Liu et al 55 have reported that OncoVEX GM-CSF can reduce not only injected but also noninjected tumors.
HSV1716 and HF10
1716 was mutated from HSV-1 to both g34.5 deletion mutant viruses. 1716 selectively replicates in dividing cells. g34.5 is related to the protein synthesis of virus replication using an interaction with dephosphorylated eIF2a in infected cells (described in G207). Replication of the g34.5-null virus is attenuated in normal cells. HF10 is described later in the section on ''our clinical trial against pancreatic cancer using oncolytic virus HF10''.
Clinical trials using oncolytic viruses against pancreas cancer
ONYX-015
A dose-escalation phase I study was carried out in Hammersmith Hospital in the United Kingdom. A total of 23 people with unresectable pancreatic cancer participated in this clinical trial. ONYX-015 injection was performed without laparotomy under computed tomography-guide (n ¼ 22 patients) and intraoperative injection (n ¼ 1 patient) into pancreatic primary tumors every 4 weeks consecutively until tumor progression. Six patients showed a 25-49% tumor regression, 11 were stable (o25% increase or decrease), and five showed tumor progression. One patient was not evaluated for response. These results showed that the intratumoral injection of ONYX-015 into primary pancreatic cancer was feasible and well tolerated at doses up to 10 11 PFU (2 Â 10 12 particles). However, viral replication was not detectable in biopsy specimens, 56 although other clinical trials using ONYX-015 detected viral replication in head and neck cancer, 57, 58 ovarian cancer, 59 and in primary and secondary liver metastasis. 60, 61 A phase I/II study using ONYX-015 for the treatment of pancreatic cancer was carried out in the Jonsson Comprehensive Cancer Center in Los Angeles, USA. In total, 21 people with pancreatic cancer were eligible for this clinical trial. ONYX-015 in doses up to 2 Â 10 11 PFU was administered via endoscopic ultrasound-guided injection into Figure 3 Cell protein kinase receptor (PKR) is stimulated by HSV-1 infection, and activated by auto-phosphorylation. Activated PKR phosphorylates eIF-2a Phosphorylated eIF-2a shut-off intra cell protein synthesis, and viral replication. HSV-1 g34.5 with cell protein phosphatase-1a dephosphorylates eIF-2a, and allows protein synthesis.
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unresectable primary pancreatic tumors once a week for 8 weeks. Two patients showed partial tumor regression, two had minor responses, six patients were stable, and 11 showed tumor progression. 62 About 80% (Hammersmith Hospital, UK) and 50% (Jonsson Comprehensive Cancer Center, USA) of patients showed tumor regression or stable symptom in those clinical trials against pancreatic cancer. In addition, combination therapy with chemotherapy or radiation improved the results of clinical trials. In a phase II clinical trial of ONYX-015 for recurrent head and neck cancers, the virus proved especially beneficial in combination with chemotherapy (cisplatin and 5-fluorouracil). 63 Clinical trial against other cancers, and potential for pancreas cancer treatment These viruses have not been used for clinical trials against pancreatic cancer but have great potential for treating many types of cancer, including pancreatic cancer. A description of these viruses would be useful to comprehend the potential of oncolytic viruses.
G207
Clinical trials of G207 have been performed mainly in the field of neurosurgery. 64, 65 MediGene Inc. reported the final result of a phase I study, using doses up to 3 Â 10 9 PFU, for brain tumors. Phase I study is designed primarily to analyze tolerance and toxicity in patients in whom all known treatments have failed to bring any benefit. Holldack of MediGene reported no toxicity related to G207 among all seven dose-escalating cohorts at the University of Alabama and Georgetown University Medical Center. After this phase I study, MediGene is now preparing a phase II trial for G207. 66 We believe G207 has great potential for the treatment of abdominal tumors also, but we have yet to find a clinical report on the use of G207 in the treatment of pancreatic cancer.
NV1020
A phase I clinical trial is now ongoing at the Memorial Sloan-Kettering Cancer Center in New York City to estimate the effectiveness of NV1020 in treating patients with colon cancer that has spread to the liver and who have not responded to previous chemotherapy. A total of 27 patients are enrolled in this study. The eligible patients have not responded to a first-line combination chemotherapy of fluorouracil plus either leucovorin calcium or irinotecan and are now candidates for intrahepatic arterial infusion pump placement. NV1020 will be injected into the hepatic artery using a catheter. Although trial for pancreatic cancer has not been initiated, the results of NV1020 for treating liver metastasis of colon cancer might also indicate some effect against liver metastasis in pancreatic cancer. 67 
OncoVEX GM-CSF
OncoVEX GM-CSF has been used in a clinical trial (phase I and II) for breast cancer, head and neck cancer, gastric cancer, and melanoma. A dose escalation study against breast cancer using 10 6 and 10 7 PFU doses has been well tolerated by direct injection in cutaneous and subcutaneous metastatic deposits. PCR detected virus in the blood that disappeared within 2 weeks. Antitumor activity has been observed as tumor necrosis and as inflammation caused by GM-CSF in both injected and uninjected tumors. 68 The results have been announced at several academic meetings.
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HSV1716
After injections of 1716 in a phase I study at doses up to 1 Â 10 5 for the treatment of malignant glioma, there have been no reports of encephalitis, adverse clinical symptoms, or reactivation of latent HSV. Four of nine patients were alive and well for 14-24 months. 70 
Comparing adenovirus and herpesvirus characteristics
Adenovirus is a nonenveloped, linear, double-stranded DNA virus with a genome size of approximately 38 kb that is comprised by icosahedral protein capsid covered with penton base protein and 12 fibers. To efficiently replicate, adenoviruses after entering the cytoplasm, induce the infected cells to enter the cell cycle by expression of the adenoviral E1 gene complex. E1A binds to and inhibits the action of the cellular tumor suppressor retinoblastoma protein (pRB). This releases pRB from the transcription factor E2F and facilitates entry into the G 1 phase of the cell cycle. E2F mediates the transcription of several cellular enzymes necessary for DNA synthesis that occurs in the S phase. The ultimate effect of immediate E1A expression is to create a cellular environment favorable to the synthesis of multiple copies of the adenoviral genome.
Herpesvirus is also a double-stranded DNA virus with a genome size of approximately 152 kb, which is four times larger than that of the adenovirus. Herpesvirus is composed of an interior icosahedral capsid containing seven structural proteins within which the viral DNA genome is found in association with core proteins. Surrounding the capsid is an amorphous matrix of proteins called the tegument, 71 which consists of approximately 12 viral components. 72 The viral envelope is the outer shell of the virus particle and possesses at least 10 unique virus-encoded glycoproteins. HSV infection is initiated at the epithelial or mucosal skin surface membranes, releasing the capsids into the cytoplasm. Once inside the cell, the capsid and tegument are transported to the nucleus where the viral DNA enters the nucleus through a nuclear pore. 73 The three stages of transcription in nucleus are known as the immediate (a), early (b), and late (g) stages. Oct-1 interacts with tegument protein VP16, and they stimulate a-gene. The product of 
Evaluation of oncolytic effects
A phase I trial of the herpesvirus showed a good dose tolerance for all attempted dosages, and phase I and II trials of an adenovirus verified the oncolytic virus effect in about 50-80% of the patients with pancreatic cancer, expressed as a tumor-reducing or tumor size-stabilizing effect. The doses of adenovirus used were from 1 Â 10 10 to 2 Â 10 12 for the clinical trial, while the herpesvirus doses were lower at 1 Â 10 6 to 3 Â 10 9 ( Table 2 ). These dosages were determined from basic research using an animal model. It is not easy to evaluate the issue of dose and the result of oncolytic effects between different viruses, each of which is counted differently. Because an adenovirus is usually counted by PFU on the 293 cell by TCID50 using a 96-well plate, and herpesvirus is counted on the Vero cell using a six-well plate (some modification would exist among laboratories). Detailed data are not shown, but we have studied the oncolytic effect of herpesvirus by comparing it with the adenovirus in an in vitro cytotoxic assay. This method using an MTT assay was briefly described in a previous paper. 74 We used Vero cells for both viruses to count the PFU of herpesvirus and TCID 50 of adenovirus in order to remove the difference in sensitivity for viruses on different cell lines, because 293 cell would be more sensitive than Vero cell to either virus infection. When we used viruses at MOI 0.1, the herpesvirus (KOS) showed a 5.5 times greater oncolytic effect against pancreatic cancer than did the adenovirus (wild-type 5) in a pancreatic cancer cell line (Capan-2), and a 9 times greater effect against a pancreatic cancer cell line (SW1990) in vitro. Those cell lines were derived from human pancreatic cancer and carried a K-ras mutation. 75, 76 When we compare viruses at the same MOI, they are found to differ in their oncolytic effects, but the oncolytic effect of each mutated virus would include some difference from the parent virus.
Current topics
Genetic Engineering
The current strategy for oncolytic virus therapy is to develop agents with increased safety and stronger tumorreducing effects. Concerning safety, a double-or triplemutation virus is generally safer than a one-point mutation virus. The chimera structure, such as NV1020, might make the virus difficult to recover to the wild type. Far from enhancing safety, increasing the number of point mutations renders the virus weak in its ability to reduce tumor volume. Researchers have been attempting to use a tumor-specific promoter to regulate the gene that 77 Results of studies on a carcinoembryonic antigen (CEA), 78 Muc-1, 79 ERBB2, amylase, and insulin show them to be possibly suitable as promoters of an oncolytic virus for the treatment of pancreatic cancer (Table 3) . A coming study of a mutated virus using a suitable promoter for pancreatic cancer will show it to resemble the albumin promoter-regulated replication-competent herpesvirus against hepatoma 80 or Muc1 promoterregulated replication competent adenovirus against breast carcinoma.
81 To achieve a stronger tumor-reducing effect, researchers are attempting to insert a therapeutic gene into the oncolytic virus genome. This strategy, called gene-directed prodrug activation therapy (GPAT), uses enzymes that are nonmammalian in origin or small quantities in human cells (Table 4) . TK from HSV and cytosine deaminase from Escherichia coli are two representative enzymes used in this approach. The HSV-TK gene is the most famous suicide gene of GPAT. HSV-TK, which is expressed in infected cells by wild-type HSV, phosphorylates ganciclovir to ganciclovir monophosphate, which is then further phosphorylated by the host cells to the toxic form, ganciclovir triphosphate, which inhibits DNA polymerase and is toxic to cells in the S phase of the cell cycle. Gene therapy using the HSV-TK gene attempts to deliver this gene preferentially to pancreatic cancer cells by a vector, and then ganciclovir is added so that the cancer cells, which now harbor the activating enzyme TK, will die. As the pioneers regarding this strategy, Boviatsis et al 82 reported long-term survival of a brain tumor model by hrR3-ganciclovir combination therapy. As these are not oncolytic viruses but active against pancreatic cancer, the regression of hepatic metastases of pancreatic cancer caused by non-replicated adenovirus-mediated HSV-TK, 83 and the regression of peritoneal dissemination of pancreatic cancer caused by liposome-mediated HSV-TK 84 have been reported. An evaluation of the bystander effect of HSV-TK and ganciclovir in experimental pancreatic cancer was also reported by Makinen et al. 85 Cytosine deaminase (CD), an enzyme found only in bacteria and fungi, catalyzes the deamination of cytosine to uracil. CD can also convert the nontoxic prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU), which is subsequently processed to 5-fluorouracil triphosphate (5-FUTP) or fluoro-2-deoxyuridine-5 0 monophosphate (5-FdUMP). 5-FUTP is then incorporated into mRNA where it interferes with mRNA processing, whereas 5-FdUMP inhibits thymidylate synthase and thereby interferes with DNA synthesis. Nakamura et al 86 reported HSV1yCD that is inserted CD in ICP6 gene area of HSV-1. They showed tumor-selective replication of virus and tumor-reducing effect against colon cancer model in the presence of 5-FC. As gene therapy against pancreatic cancer using replication incompetent virus vector, CD is delivered by adenovirus vector to pancreatic cancer cells and then followed by 5-FC, as described in an experimental model. 87 As one more example, this time against brain cancer, Cytochrome P450 2B1(CYP2B1) activates cyclophosphamide and changes it to acrolein and phosphoramide-mustard. Chase et al 88 inserted the gene corresponding to CYP2B1 into the ICP6 gene area of HSV-1 and reported the function of this 
Pet image scanning
Positron emission tomography (PET) has great potential to evaluate the virus oncolytic effect in clinical trials, because it is very helpful to estimate the viability of a tumor after virus infection, while computer tomography (CT) and magnetic resonance imaging (MRI) reflect the size of the tumor. CT and MRI are not adequate for therapy evaluation and tumor grading, since changes in tumor volume and changes in tumor viability are not very well correlated. 18 Fluoro-2-deoxy-D-glucose (FDG) is the best-known radiopharmaceutical substrate for PET. FDG-PET is a derivative of tumor growth, whereas glucose consumption is aggressively increased in tumor growth. FDG-PET is very helpful for evaluation of the oncolytic effect using many types of virus. On the other hand, to determine virus location and virus activity, 2-
is very useful. FIAU is a selective substrate for viral thymidine kinase (TK). FIAU enters cells, and is modified and trapped in cells by TK enzyme molecules. Herpes simplex virus has the UL27 gene corresponding to TK in their base gene naturally, and several viruses acquire the gene corresponding to TK as a suicide gene by a genetic engineering technique. Jacobs et al 90 showed an accumulation of FIAU in cells that were infected to HSV in vivo, and FIAU accumulated on the line of the rim surrounding the necrotic part of the tumor on rats bearing 9L gliosarcoma. They also showed the beneficial function of FIAU-PET in clinical trials using cationic liposome including TK gene against human brain tumor. 91 HSV-TK expression and vector-mediated TK gene expression is imaged by FIAU-PET, and the therapeutic effect was discussed by FIAU-PET. PET scan imaging is highly recommended for the evaluation of oncolytic virus therapy.
Our clinical trial against pancreatic cancer using oncolytic virus HF10
We are preparing to conduct a clinical trial against pancreatic cancer using HSV-1 strain HF clone (HF10). HF10 is a spontaneous mutated virus from strain HF, 19 and has a deletion of 3.9-kb in the right end of the UL and UL/IRL junction, resulting in the loss of UL56 expression. A 2.3 kb deletion and extensive converted rearrangement (UL52-UL55) were also observed in the left end of UL. The tumor-reducing effect of this virus is stronger than that of hrR3 in the peritoneal disseminated mouse model of NfSa Y83 (mouse fibrosarcoma). 92 We showed that the mouse antitumor immune effect is triggered by injecting this virus into a mouse peritoneal disseminated model, and that the rechallenge of the tumor inoculation is rejected by the host immune system. 93 We already have conducted a Phase I clinical trial using this virus against advanced recurrent breast cancer. Six patients participated in this trial. Those patients received several virus injections of various contents from 1 Â 10 4 to 5 Â 10
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. The results of this clinical trial revealed a great tumorreducing effect without any type of side effect. The final pathological findings showed a 30-100% tumor cellreducing effect, and complete tumor cell disappearance in one patient. Detailed data were already published. 94 Those results encouraged us, and we are planning to perform a Phase I clinical trial against nonresectable advanced pancreatic cancer. It has already been approved for clinical trial by the ethics committee of Nagoya University School of Medicine.
Conclusion
Biological technology designed for the handling of DNA has been developed, and we are actively seeking a new technique for therapeutic strategies to deal with pancreatic cancer. Gene therapy will certainly be among them. Oncolytic virus therapy has shown strong tumor-reducing effects against many types of cancer. Clinical trials have been started, mainly to confirm safety. The oncolytic effect itself is strong enough in gene therapy even without therapeutic genes such as cytosine deaminase, cytochrome P450, or endostatin. Oncolytic viruses, including these therapeutic genes, are expected to produce major therapeutic effects for dealing with cancer. We look forward to seeing the results of human clinical trials incorporating this new therapeutic strategy and technology.
